MedTrace Logo

Effects of Continuous Versus Single Dose Spinal Anesthesia in Octagenerians Undergoing Hip Surgery

NCT05418374 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-06-14

No results posted yet for this study

Summary

Continuous spinal anesthesia (CSA) is an anesthetic technique that offers several clinical advantages for anesthesia and analgesia in elderly patients. The level of sensory blockade can be titrated to the desired dermatomal level with great precision with intrathecal (IT) catheters, allowing better control of the hemodynamic consequences of sympathetic blockade associated with spinal anesthesia compared to epidural or single shot spinal techniques. Better control of hemodynamics maybe advantageous in patients with cardiac disease in whom administration of lower doses of local anesthetics is advantageous. Greater numbers of patients are presenting for surgery with aging-related pre-existing conditions, which places them at greater risk of an adverse outcome, such as cardiac or pulmonary disease or diabetes mellitus. CSA allows incremental dosing of an intrathecal local anesthetic providing fewer hemodynamic alterations. While spinal anesthesia is widely used anesthetic technique in lower limb surgery in the elderly, it induces more hemodynamic instability due to high blockage effect which largely limits the use of conventional dose of spinal anesthesia in high risk elderly patients

Conditions

  • Octagenerian Population Undergoing Hip Surgeries

Interventions

PROCEDURE

Continous Spinal Anestheisa

Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hany M. Elzahaby, M.D. · AinShams University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
80 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418374 on ClinicalTrials.gov